SLC2A11 and neoplasm: Recent studies have identified novel therapeutic targets in bladder cancer, such as the ETS transcription factor ETV4 driving neutrophil-mediated metastasis 70, a pathogenic SLC2A11-MIF fusion protein promoting tumor progression 71, and the ubiquitination enzyme UBE2S facilitating lymphatic spread 72.